ReviewCold Spring Harbor perspectives in medicine2012
β-thalassemia intermedia: a clinical perspective.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.The Cochrane database of systematic reviews · 2016Pooled it
- Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.British journal of haematology · 2017Trial
- Multisystem Complications in Non-Transfusion-Dependent β-Thalassemia Intermedia: A Case Highlighting the Need for Early Intervention.Clinical case reports · 2026Article
- Leg Ulcers in Thalassaemia: A Comparative Retrospective Review of Transfusion-Dependent and Non-Transfusion-Dependent Patients.International wound journal · 2026Article
- Paraspinal Extramedullary Hematopoiesis in a Transfusion-Dependent Beta-Thalassemia Patient: A Case Report.Cureus · 2025Article
- Ischemic Stroke as the Initial Presentation of Sickle Beta Thalassemia in an Adolescent: A Case Report.Cureus · 2025Article
- Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Predicting Thalassemia Using Feature Selection Techniques: A Comparative Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Article
- Article
- Bioinformatic Tools for the Identification of MicroRNAs Regulating the Transcription Factors in Patients with β-Thalassemia.Bioinformatics and biology insights · 2022Review
- Subclinical Left Ventricular Dysfunction in Children and Adolescence With Thalassemia Intermedia.Frontiers in pediatrics · 2022Article
- Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine.Scientific reports · 2021Article
- Correlation of Serum Ferritin and Liver Iron Concentration with Transient Liver Elastography in Adult Thalassemia Intermedia Patients with Blood Transfusion.Journal of blood medicine · 2021Article
- Anti-Platelet Aggregation and Anti-Cyclooxygenase Activities for a Range of Coffee Extracts (Molecules (Basel, Switzerland) · 2020Article
- Article
- Unusual cause of mediastinal widening.BMJ case reports · 2020Article
- HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review.Journal of clinical pharmacy and therapeutics · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our understanding of the molecular and pathophysiological mechanisms underlying the disease process in patients with β-thalassemia intermedia has substantially increased over the past decade. Earlier studies observed that patients with β-thalassemia intermedia experience a clinical-complications profile that is different from that in patients with β-thalassemia major. In this article, a variety of clinical morbidities are explored, and their associations with the underlying disease pathophysiology and risk factors are examined. These involve several organs and organ systems including the vasculature, heart, liver, endocrine glands, bone, and the extramedullary hematopoietic system. The effects of some therapeutic interventions on the development of clinical complications are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.